

William Slattery, CFA Vice President Listing Qualifications

By Electronic Mail

November 5, 2013

Mr. Jeffrey Thomas Chief, IT Services Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549

Dear Mr. Thomas:

This is to certify that on November 1, 2013 The Nasdaq Stock Market (the "Exchange") received from Karyopharm Therapeutics Inc. (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following security:

Common Stock, \$0.0001 par value per share

We further certify that the security described above have been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking effectiveness of the Form 8-A 12(b) concurrently with effectiveness of its 1933 Act Registration Statement, and we hereby join in such request.

Sincerely,

William Lattery



**Received SEC** 

NOV 0 5 2013

Washington, DC 20549 CERTNAS File No. 001-36167